RxDoctor Payments DataLook up a doctor →

Tamara Miller, MD

Neurology · Fort Collins, CONPI 1982659017

Payments from drug & device makers

$7,419,805in general payments, 2019–2025

Across 3,611 payments — averaging $2054.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.9M
  • AbbVie$1.6M
  • Biogen$1M
  • Sanofi$878K
  • TG Therapeutics, Inc.$606K
  • EMD Serono, Inc.$210K
  • plus $1.2M from 54 others
$7,374in research payments, 2019–2025

Across 19 payments — averaging $388.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$5K
  • Pfizer$2K
  • Sanofi US Services Inc.$997

What the payments were for

  • Consulting fees$136,91110%
  • Speaking & faculty fees$1,120,30479%
  • Travel & lodging$107,4398%
  • Food & beverage$60,9444%
  • Education$6860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.72$1,905,853
AbbVie(2 entities)777$1,597,710
Biogen200$1,025,504
Sanofi300$878,142
TG Therapeutics, Inc.184$606,092
EMD Serono, Inc.291$209,520
Adamas Pharmaceuticals, Inc.45$195,977
Novartis124$183,669
AstraZeneca(2 entities)71$134,215
Genentech USA, Inc.165$119,649
Amgen(2 entities)176$92,380
F. Hoffmann-la Roche AG18$61,118
Biohaven Pharmaceutical Holding Company Ltd.90$52,030
Lundbeck LLC106$51,601
Biohaven Pharmaceuticals, Inc.81$50,337
Ipsen Innovation27$40,616
Bristol Myers Squibb74$35,781
Pfizer95$30,309
Teva Pharmaceuticals USA, Inc.80$26,693
Lilly USA, LLC124$21,688
Roche Products Limited12$21,663
Mallinckrodt Enterprises LLC30$19,527
E.r. Squibb & Sons, L.L.C.22$18,300
Impel Pharmaceuticals Inc.7$10,769
MDD US Operations, LLC41$8,242
Mallinckrodt Hospital Products Inc.72$7,834
H. Lundbeck A S4$6,654
UCB, Inc.50$1,392
Livanova USA, Inc.3$1,160
SK Life Science, Inc.31$686
Acorda Therapeutics, Inc16$404
Supernus Pharmaceuticals, Inc.21$376
GRT US Holding, Inc.19$353
Amneal Pharmaceuticals LLC14$267
Neurocrine Biosciences, Inc.17$252
CSL Behring11$228
Neurelis, Inc.8$197
Avanir Pharmaceuticals, Inc.10$181
Scilex Pharmaceuticals Inc.10$176
Johnson & Johnson(2 entities)7$160
Banner Life Sciences, LLC8$157
Eisai Inc.8$147
Merz Pharmaceuticals, LLC9$136
Tanabe Pharma America, Inc.7$133
ANI Pharmaceuticals, Inc.5$120
Grifols USA, LLC6$120
Argenx US, Inc.5$107
Jazz Pharmaceuticals Inc.4$103
Medtronic1$101
Abbott4$98
Acadia Pharmaceuticals Inc4$85
Bausch Health US, LLC4$82
Vanda Pharmaceuticals Inc.2$59
Averitas Pharma Inc.3$56
Catalyst Pharmaceuticals, Inc.3$54
Assertio Therapeutics, Inc.2$44
Life Molecular Imaging Ltd4$42
Axsome Therapeutics, Inc.2$41
Arbor Pharmaceuticals, Inc.2$40
Otsuka America Pharmaceutical, Inc.2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,419,805 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$2,413,319
Medicare patients
321
Services billed
120,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab45$437,914
CopaxoneGlatiramer Acetate24$142,509
TecfideraDimethyl Fumarate13$120,814
Nurtec OdtRimegepant Sulfate76$114,645
VumerityDiroximel Fumarate13$113,328
UbrelvyUbrogepant55$81,875
Dalfampridine ErDalfampridine199$71,700
Emgality PenGalcanezumab-Gnlm65$59,865
Aimovig AutoinjectorErenumab-Aooe63$55,906
FingolimodFingolimod Hcl25$53,735
Teriflunomide124$37,995
NuedextaDextromethorphan Hbr/Quinidine26$35,175
Ajovy SyringeFremanezumab-Vfrm37$24,045
QuliptaAtogepant22$23,901
VimpatLacosamide17$23,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$1,025,504$234,14226 claims
Teva Pharmaceuticals USA, Inc.Copaxone$26,693$142,50924 claims
PfizerNurtec Odt, Zavzpret$30,309$126,25587 claims
AbbVieUbrelvy, Qulipta$1,597,710$105,77677 claims
Avanir Pharmaceuticals, Inc.Nuedexta$181$35,17526 claims
UCB, Inc.Vimpat$1,392$23,69917 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$267$1,12112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.

Other neurology in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →